EXPRESSION AND PROGNOSTIC VALUE OF VERSICAN AND Ki 67 IN CANINE CUTANEOUS AND SUBCUTANEOUS TUMORS
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
KARNATAKA VETERINARY, ANIMAL AND FISHERIES SCIENCES UNIVERSITY, BIDAR
Abstract
To evaluate the prognostic value of versican and Ki 67, the present study was
carried out in 112 cases of canine cutaneous and subcutaneous tumors. On
histopathological examinations various round cell, epithelial and mesenchymal tumors
were identified. There were 78 cases of malignant and 34 benign tumors and the
epithelial neoplasms were the most common type of tumors observed. Quantification of
versican and Ki 67 mRNA by qRT-PCR in various cutaneous and subcutaneous tumors
revealed higher expression of both in malignant tumors compared to benign tumors.
Statistical analysis revealed a significant (P< 0.05) difference in the expression of
versican and Ki 67 between malignant and benign tumors. To determine the prognostic
value of versican and Ki 67 expression a median cut off value of gene fold expression
was calculated which was 1.65 for versican and 4.29 for Ki 67. The versican and Ki 67
expression values were compared between the various post surgical outcome groups such
as death, recurrence and disease free alive status which showed a statistically significant
(P< 0.05) difference in the versican expression between alive and recurrence group and
alive and dead group, while between recurrence and dead group there was no statistically
significant (P> 0.05) difference. Similarly, there was a significant (P< 0.05) difference in
Ki 67 expression between alive and recurrence group and alive and dead group, also a
significant (P< 0.05) difference was observed between recurrence and dead group. In
addition, statistical analysis of Kaplan - Meier curves of follow up period of dogs
revealed statistically significant (P< 0.01) difference in survival rate and recurrence rate
between dogs having versican and Ki 67 overexpression and underexpression values. The
mean survival period was observed to be four months for dogs with overexpression of
both versican and Ki 67, further undefined for dogs with underexpression of both
versican and Ki 67. The median recurrence period for versican and Ki 67 overexpression
score was found to be six and five months respectively and for underexpression score it
was eight months in both versican and Ki 67. Also, there was a significant (P< 0.01)
moderate to strong positive correlation between expression levels of versican and Ki 67
in benign and malignant tumors with r value 0.6328 and 0.5850 respectively.
Key words: Versican, Ki 67, quantification, prognostic value, correlation